Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study

Affiliations

• ¹ Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Japan.
• ² First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
• ³ Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.
• ⁴ Department of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan.
• ⁵ Department of Hematology, Fujisawa City Hospital, Fujisawa, Japan.
• ⁶ Department of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan.
• ⁷ Department of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan.
• ⁸ Division of Hematology, Department of Internal Medicine, National Hospital Organization Tokyo Medical Center, Meguro-ku, Japan.
• ⁹ Hematology and Oncology Division, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
• ¹⁰ Kissei Pharmaceutical Co., Ltd., Tokyo, Japan.
• ¹¹ Department of Blood Transfusion, Osaka University Hospital, Suita, Japan.